Merck’s combination therapy in lung cancer fails a Phase 2 clinical trial
Merck & Co. Inc. said late Thursday that its combination therapy of vibostolimab and Keytruda did not outperform chemotherapy in a Phase 2 clinical trial of…
Merck’s combination therapy in lung cancer fails a Phase 2 clinical trial
